We chose the anti-mitotic drug Paclitaxel25 and the MEK1/2 inhibitor Trametinib26 as established anti-cancer drugs, and an AKT inhibitor MK-220627 as a candidate anti-cancer drug, for the cytotoxicity analyses. Here, MAP2K1 is linked to cancer.